CYTOPOINT™ is a novel monoclonal antibody (mAb) therapy licensed by the USDA to help reduce clinical signs associated with atopic dermatitis in dogs. As a mAb, CYTOPOINT is specifically designed to target and neutralize cytokine IL-31, a key itch-inducing cytokine in canine atopic dermatitis.
- CYTOPOINT begins working within 1 day and delivers 4 to 8 weeks of relief from the clinical signs of canine atopic dermatitis.
- It is safe for dogs of all ages, even those with concomitant diseases, and can be used with many common medications.
Let us know what you think.
Have an idea for a course, a question, or need assistance?